Shanghai Sanyou Medical Co., Ltd. is a medical devices corporation founded in 2005 that focuses on the R&D, production and sales of orthopedic implants, particularly spinal implants and implants for trauma patients. It is one of the few enterprises in China's orthopedic market with the innovative R&D capabilities.
Since its establishment, the company has attached great importance to the updating and iteration of products. Under the leadership of chairman Michael Mingyan Liu, the company has established a complete product R&D system, with international advanced R&D equipment and project management system. This allows Sanyou to produce technologically advanced, effective and reliable products. By the end of 2020, the company has obtained 23 Class III Registration Certificate of medical device products and 121 patents, including 28 domestic invention patents, 1 American, 1 Japanese and 1 Australian invention patent, 88 domestic utility model patents, 1 German utility model patent and 1 domestic design patent. The company and its products have gained national recognition, winning awards including the first prize of Excellent Scientific Research Achievement Award of Colleges and Universities, the first prize of Scientific Progress Award, the second prize of China's Medical Science and Technology award. In 2019, the company's spine products ranked second in the market share of domestic enterprises and fifth in the market as a whole.
In the future, the company will combine its own capabilities with strong government support for domestic innovation to continue to increase investment in research, develop innovative therapies and products, and vigorously increase investment in market promotion and product training. The company will strive for a substantial increase in market share, further enrich orthopedic product series, and pursue opportunities in new fields such as sports medicine. We will also promote innovation through the application of new materials, surface modification of biomaterials and 3D printing, and continuously enhance the company's value, so as to realize the sustainable, healthy and rapid development of the company and maximize the interests of investors.
| Full name | Shanghai Sanyou Medical Co., Ltd. |
|---|---|
| Abbreviations | Sanyou Medical |
| Code | 688085 |
| Founded | 2005-04-19 |
| Listing | 2020-04-09 |
| Domicile | No.385 Huirong Road, Jiading Industrial Zone, Jiading District, Shanghai |
| ir@sanyou-medical.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Special Equipment Manufacturing Industry（C35） |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.63 | 0.64 | 0.40 |
| R&D expenditure as a % of operating revenue | 8.69% | 5.21% | 5.99% |
| Operating Revenue | 390,432,505.51 | 354,319,330.18 | 222,312,864.19 |
| Net Income | 118,558,789.47 | 98,059,846.65 | 61,969,780.65 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 390.43 | 354.32 | 222.31 |
| Operating Costs | 35.63 | 30.96 | 25.46 |
| Operating Income | 130.38 | 109.34 | 68.36 |
| Pretax Income | 136.95 | 113.96 | 71.66 |
| Income Tax | 18.39 | 15.90 | 9.69 |
| Net Income | 118.56 | 98.06 | 61.97 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1,440.93 | 342.63 | 266.39 |
| Non-current Assets-Total | 229.75 | 208.85 | 122.19 |
| Total Assets | 1,670.67 | 551.48 | 388.58 |
| Liabilities | |||
| Current Liabilities-Total | 123.68 | 106.57 | 40.26 |
| Non-current Liabilities-Total | 12.57 | 7.10 | 8.08 |
| Total Liabilities | 136.25 | 113.67 | 48.34 |
| Stockholder's Equity | |||
| Share Capital | 205.33 | 154.00 | 154.00 |
| Retained Profits | 246.88 | 140.43 | 52.26 |
| Total Owners' Equity | 1534.43 | 437.81 | 340.24 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 77.52 | 61.72 | 19.79 |
| Net Cash Flows-Investing | -830.39 | -49.56 | -17.77 |
| Net Cash Flows-Financing | 978.20 | -0.49 | -10.78 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| QM5 LIMITED | 37.95 | 18.48% |
| 徐农 | 26.81 | 13.06% |
| LIU Michael Mingyan | 22.22 | 10.82% |
| 南通宸弘股权投资合伙企业（有限合伙） | 19.60 | 9.55% |
| 赣州泰宝股权投资合伙企业（有限合伙） | 14.45 | 7.04% |
| FAN DAVID | 14.15 | 6.89% |
| 平潭泰格盈科创业投资合伙企业（有限合伙） | 4.17 | 2.03% |
| 混沌天成三友医疗科创板员工持股计划10号集合资产管理计划 | 3.95 | 1.92% |
| 交通银行股份有限公司－万家行业优选混合型证券投资基金（LOF） | 3.66 | 1.78% |
| 招商银行股份有限公 司－万家经济新动能混合型证券投资基金 | 3.00 | 1.46% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.